Expectoration of large bronchial casts secondary to the treatment of chronic hepatitis c with pegylated interferon and ribavirin: [letter to the editor]

Araújo, Evaldo Stanislau Affonso de; Campos, Aleia Faustina; Yamashiro, Juliana; Mello, Evandro Sobrosa; Takagaki, Teresa; Barone, Antonio Alci.
Clinics ; 65(7): 745-748, 2010. ilus
Artigo em Inglês | LILACS | ID: lil-555509

Documentos relacionados

  1. [Analysis of ineffective antiviral therapy with pegylated interferon and ribavirin in a patient with chronic hepatitis C infected with HCV genotype 2].
  2. Drug-Induced Subacute Cutaneous Lupus Erythematosus in a Patient Receiving Therapy for Chronic Hepatitis C.
  3. The Severity of Depressive Symptoms as an Independent Predictor of Sustained Virological Response During Treatment of Hepatitis C With Pegylated Interferon-α2a and Oral Ribavirin.
  4. Pharmacological management of adverse events during treatment of chronic viral hepatitis in three Ivorian university hospitals
.
  5. Efficacy and Safety of Direct Acting Antivirals for the Treatment of Mixed Cryoglobulinemia.
  6. Treatment for chronic hepatitis E virus infection: A systematic review and meta-analysis.
  7. Pharmacological interventions for acute hepatitis C infection: an attempted network meta-analysis.
  8. Risk Factors for Treatment Discontinuation Caused by Adverse Events When Using Telaprevir, Peginterferon, and Ribavirin to Treat Chronic Hepatitis C: A Real-World Retrospective Cohort Study.
  9. Safety Profile of Telaprevir-Based Triple Therapy in Elderly Patients: A Real-World Retrospective Cohort Study.
  10. How hepatitis C patients manage the treatment process of pegylated interferon and ribavirin therapy: a qualitative study.